PMC4518450_01
(A) Steady-state maraviroc log concentration-time curve after a 300-mg dose (given at time 0) in the case patient (solid squares) compared with previously reported steady-state maraviroc log concentration-time curves after repeated maraviroc doses of 300 mg every 12 hours in subjects with normal renal and hepatic function (open diamonds). (B) Steady-state raltegravir log concentration-time curve after a 400-mg dose (given at time 0) in the case patient (solid squares) compared with previously reported steady-state raltegravir log concentration-time curves after repeated raltegravir doses of 400 mg every 12 hours in subjects with normal renal and hepatic function (open diamonds).
nihms335708f1.jpg
PMC4518450_01_nihms335708f1.jpg
F1
As noted in Figure 1, the postdose concentrations at 2, 24, 36, and 56 hours showed a rapid early-phase decline for both drugs, followed by a much slower terminal elimination phase.